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ABSTRACT
The class Zygomycetes is divided into two orders, Mucorales and Entomophthorales. These two orders
produce dramatically different infections. Genera from the order Mucorales (Rhizopus, Mucor,
Rhizomucor, Absidia, Apophysomyces, Cunninghamella and Saksenaea) cause an angioinvasive infection
called mucormycosis. Mucormycosis presents with rhino-orbito-cerebral, pulmonary, disseminated,
cutaneous, or gastrointestinal involvement. Immunocompromising states such as haematological
malignancy, bone marrow or peripheral blood stem cell transplantation, neutropenia, solid organ
transplantation, diabetes mellitus with or without ketoacidosis, corticosteroids, and deferoxamine
therapy for iron overload predispose patients to infection. Mucormycosis in immunocompetent hosts is
rare, and is often related to trauma. Mortality rates can approach 100% depending on the patient’s
underlying disease and form of mucormycosis. Early diagnosis, along with treatment of the underlying
medical condition, surgery, and an amphotericin B product are needed for a successful outcome. Genera
from the order Entomophthorales produce a chronic subcutaneous infection called entomophthoramy-
cosis in immunocompetent patients. This infection occurs in tropical and subtropical climates. The genus
Basidiobolus typically produces a chronic subcutaneous infection of the thigh, buttock, and ⁄ or trunk.
Rarely, it has been reported to involve the gastrointestinal tract. The genus Conidiobolus causes a chronic
infection of the nasal submucosa and subcutaneous tissue of the nose and face. This paper will review
the clinical manifestations, diagnosis and treatment of mucormycosis and entomophthoramycosis.
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INTRODUCTION
The class Zygomycetes is divided into two orders,
Mucorales and Entomophthorales (Table 1). Mem-
bers of these two orders produce dramatically
different infections. In general, members of the
order Mucorales cause acute, angioinvasive infec-
tions in immunocompromised patients with mor-
tality rates exceeding 60% [1]. In contrast,members
of the order Entomophthorales cause chronic
subcutaneous infections in immunocompetent
patients from subtropical and tropical regions.
The terms phycomycosis and zygomycosis have
previously been used to describe both forms of
infection. Given their distinct clinical presenta-
tions, the term ‘mucormycosis’ should be reserved
for those infections caused by Mucorales, and the
term ‘entomophthoramycosis’ for those caused by
Entomophthorales [2]. This paper will review the
clinical manifestations, diagnosis and treatment of
mucormycosis, and brieﬂy, those of entomoph-
thoramycosis.
MUCORMYCOSIS
After aspergillosis and candidiasis, mucormycosis
is the third most common invasive fungal infection
[3]. It represents 8.3–13% of all fungal infections
encountered at autopsy in haematology patients
[4,5]. The most commonly recovered genera in-
clude Mucor, Rhizopus, Rhizomucor, Absidia,
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Apophysomyces,Cunninghamella, and Saksenaea [3,6].
Mortierella wolﬁ and Syncephalastrum racemosum
play questionable roles as human pathogens [7–9].
Five major forms of infection exist—rhino-
orbito-cerebral, pulmonary, disseminated, cuta-
neous, and gastrointestinal. Mucorales enter the
human host through inhalation, percutaneous
inoculation or ingestion [9]. Mucormycosis typ-
ically affects patients with at least one of the
following immunocompromising states—haema-
tologic malignancy, neutropenia, receipt of high-
dose corticosteroids, diabetes mellitus, diabetic
ketoacidosis, organ transplantation, deferoxamine
therapy, trauma and burns (Table 2) [10,11].
Immunocompetent patients rarely develop
mucormycosis [12].
The diagnosis of mucormycosis is challenging.
In a review of 185 cases of disseminated
mucormycosis, Ingram et al. found that an ante
mortem diagnosis was made in only 9% of cases
[13,14]. The site of infection inﬂuences physicians’
abilities to make a diagnosis. In pulmonary
mucormycosis, 28–74% of cases were diagnosed
while patients were alive [5,10,11,15]. In the largest
reported single institutional series of mucormy-
cosis cases [129 over a 10-year period (1990–99)],
Chakrabarti et al. observed that rhino-orbito-cer-
ebral (91%) and cutaneous (100%) mucormycosis
were most reliably diagnosed ante mortem,
Table 1. Fungi from the class
Zygomycetes reported as causing
infections in humans (older nomen-
clature in parentheses)
Class: Zygomycetes
Order: Mucorales Entomophthorales
Genus: Mucor Basidiobolus
M. racemosus, B. ranarum, (B. haptosporus)
M. circinelloides
M. ramosissimus Conidiobolus
M. indicus C. coronatus
M. hiemalis (Entomopthora coronata)
C. incongruus
Rhizopus
R. arrhizus (R. oryzae)
R. rhizopodiformis
R. azygosporus
R. stolonifer
R. schipperae
R. microsporus var. microsporus
var. rhizopodiformis
var. oligosporus
Rhizomucor
R. pusillus
Absidia
A. corymbifera
Apophysomyces
A. elegans
Cunninghamella
C. bertholletiae
Saksenaea
S. vasiformis
Cokeromyces
C. recurvatus
Adapted from Ribes et al. [9].
Table 2. Major risk factors for mucormycosis
Haematological malignancy
Leukaemia
Lymphoma
Multiple myeloma
Neutropenia
Pharmacologic immunosuppression
Antineoplastic chemotherapy
Corticosteroid therapy
Antirejection therapy
Diabetes mellitus (Types I and II) with or without
diabetic ketoacidosis
Solid organ transplantation
Bone marrow and peripheral blood stem cell
transplantation
Deferoxamine therapy
Burns
Trauma
Malnutrition in children
Intravenous drug use
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compared to pulmonary (31%), renal (44%),
gastrointestinal (0%) and disseminated (0%)
forms [16]. A high index of clinical suspicion
and biopsy accessibility inﬂuence physicians’
diagnostic abilities as well.
Epidemiology
The clinical presentation of mucormycosis
depends on the patient’s underlying medical con-
dition. Overall, rhino-orbito-cerebral mucormyco-
sis is themost common form (44–49%), followedby
cutaneous (10–16%), pulmonary (10–11%), dis-
seminated (6–11.6%) and gastrointestinal (2–11%)
presentations [2,17,18]. In patients with haem-
atological malignancy, pulmonary, followed
by disseminated and rhino-orbtio-cerebral pres-
entations, are the most common [6]. Diabetics
usually develop rhino-orbito-cerebral or pulmon-
ary mucormycosis [11,18].
Some studies have suggested a rising incidence
of mucormycosis. At M. D. Anderson Cancer
Center in Texas, for example, the number of cases
increased from eight per 100 000 admissions
during 1989–93 to 17 per 100 000 admissions
during 1994–98 [6]. The overall incidence of
mucormycosis at autopsy at M. D. Anderson
Cancer Center was 0.7% (12 of 1765 autopsies)
during the period 1989–98 [6]. Among those with
haematological malignancies it was 1.9% (12 of
624 autopsies) [6]. In Japan, Funada and Matsuda
found a similar incidence of 2.1% at autopsy in
patients with acute leukaemia [5]. At the Memor-
ial Sloan-Kettering Cancer Center in New York,
Meyer et al. reported an incidence of 4% at
autopsy among patients with leukaemia from
the period 1962–71. These investigators reported a
higher incidence during the last 2 years (1970–1)
compared to the ﬁrst 2 years (1962–3), 8% vs.
1.1%, respectively [19]. Mucormycosis afﬂicts
approximately 0.9–1.9% of allogeneic bone mar-
row transplant patients [13,20–23].
Mucormycosis constitutes a small proportion of
invasive fungal infections in solid organ trans-
plant recipients. The incidence of mucormycosis
in patients with renal transplants ranges from 0.2
to 1.2%, with liver transplants from 0 to 1.6%,
with heart transplants from 0 to 0.6%, and with
lung transplants from 0 to 1.5% [24–36]. The
corresponding incidence of all invasive fungal
infections (same institutions) in patients with
renal transplants ranges from 3.5 to 6.1%, with
liver transplants from 11 to 42%, with heart
transplants from 2.2 to 6.3%, and with lung
transplants from 9 to 27.5% [24–39]. Singh et al.
reported that 80% of cases in solid organ trans-
plant recipients occurred within 6 months of
transplantation [40].
Mucormycosis has been reported from all
corners of the world. A few papers have com-
mented on a possible seasonal variation in Mu-
corales infection [5,41]. In Israel, Talmi et al. noted
that 16 of their 19 cases of rhino-orbito-cerebral
mucormycosis occurred between August and
November [41]. In Japan, Funada and Matsuda
noted a similar seasonal variation among haema-
tology patients, with six of seven cases of pul-
monary mucormycosis having developed
between August and September [5].
Microbiological diagnosis
Mucorales are ubiquitous saprophytes found in
soil and decaying organic matter [42,43]. They
grow on most routine bacterial (i.e. sheep blood
agar, chocolate agar) and fungal culture media
(i.e. Sabouraud dextrose agar, inhibitory mould
agar, potato dextrose agar) at a wide range of
temperatures, 25–55 C [44]. Mucorales present in
clinical specimens will grow at 37 C [45] and
form ﬂuffy white, grey, or brownish colonies that
rapidly ﬁll the Petri dish within 1–7 days [9,18].
Mechanical homogenization of tissue specimens
can lower the yield of cultures [9,11,46].
Several different techniques (e.g. treatment with
20% potassium hydroxide, Gomori’s methenam-
ine silver staining, haematoxylin & eosin staining,
periodic acid-Schiff staining) can be used for direct
microscopic detection of Mucorales. Although on
microscopy Mucorales have been classically
described as having broad (10–50 lm), ribbon-like
aseptate hyphae with right-angle branching,
the hyphae are actually pauciseptate, and the
angle of hyphal branching can vary from 45 to 90
[44,47–51]. Histopathologically, angioinvasion
with surrounding tissue infarction are often ob-
served. Frater et al. noted perineural invasion in
90% of biopsies, a phenomenon that may explain
why Mucorales causes rhino-orbital-cerebral dis-
ease [48,52,53]. Mucorales produce a variable
inﬂammatory response. In a single institutional
review of 20 cases, Frater et al. noted a neutrophilic
inﬂammatory response in 50% of cases, a mixture
of neutrophils and granulomas in 25% of cases,
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granulomas alone in 5% of cases, and no inﬂam-
matory response in 20% of cases [48].
Risk factors
Haematological malignancy is a major risk factor
for mucormycosis, with leukaemia or lymphoma
being the underlying diagnosis in the majority of
patients [14]. Other haematological conditions
associated with infection include multiple myel-
oma, myelodysplastic syndrome, aplastic anae-
mia and sideroblastic anaemia [1,6,54,55]. Patients
with solid tumours rarely develop mucormycosis
[14]. At M. D. Anderson Cancer Center, Kontoyi-
annis et al. found no cases of mucormycosis
among patients with solid tumours over a 10-year
period; all positive cultures represented colonisa-
tion [6].
Malignancy relapse, neutropenia (< 500 neu-
trophils ⁄mm3), graft-versus-host disease, and
immunosuppressive therapy (steroids and ⁄ or
chemotherapy) received in the month before
diagnosis have been identiﬁed as risk factors for
mucormycosis [4,6]. Morrison and McGlave
found that among 13 bone marrow transplant
patients (10 allogeneic and three autologous), ﬁve
experienced relapse of their underlying disease at
diagnosis, including all autologous transplant
recipients [22]. In a retrospective review of inva-
sive mould infections, Baddley et al. found that
graft-versus-host disease, corticosteroids and
receipt of an allogeneic bone marrow transplant
from a matched unrelated, haplotype-identical or
umbilical cord blood donor were risk factors for
mucormycosis by univariate analysis. Only corti-
costeroid use remained a signiﬁcant risk factor by
multivariate analysis (p ¼ 0.018, odds ratio > 20)
[20].
Among studies from various institutions,
40–100% of haematology patients with mucormy-
cosis had been neutropenic at diagnosis [6,20–22].
Nosari et al. reported the median duration of
neutropenia before diagnosis as 10 days (range,
5–18 days) while Kontoyiannis et al. found a
mean duration of 16 days (range, 5–54 days) [4,6].
Patients who undergo solid organ transplan-
tation are at risk for mucormycosis as well,
particularly if they are treated for acute rejection
with high-dose corticosteroids, OKT3, or anti-
thymocyte globulin [27,36,39,56]. Cytomegalovi-
rus infection in solid organ transplant recipients
has been associated with the development
of mucormycosis [32,56,57]. In liver transplant
recipients, high intraoperative blood transfu-
sion requirements, bacterial infections and
retransplantation for graft failure place
patients at greater risk for mucormycosis [24,26,
32,36,37,56,58,59].
Deferoxamine therapy for iron or aluminium
overload, especially in haemodialysis patients, is
associated with mucormycosis [60,61]. Over 75%
of reported dialysis patients with mucormycosis
had received deferoxamine at the time of diagno-
sis [62]. Patients with other iron-overload condi-
tions requiring deferoxamine therapy such as
myelodysplastic syndrome, b-thalassaemia and
sideroblastic anaemia have also developed
mucormycosis [61,63]. The long half-life of defe-
roxamine in haemodialysis patients may uniquely
predispose them to infection. The mean duration
of deferoxamine therapy before infection has
ranged from 8 to 9.3 months (range, 19 days to
20 months) [60,61]. Rhizopus spp. have been the
predominant organism recovered on culture
[60,61]. Daly et al. found that more than one-half
of the patients had disseminated infection, and
one-quarter had isolated rhinocerebral disease
[61]. Mortality rates approached 90% in
these patients [60,61]. Today, far fewer cases of
mucormycosis are expected in dialysis patients,
given that therapeutic erythropoietin has reduced
the need for frequent blood transfusions.
Iron overload, in itself, is also a risk factor for
mucormycosis [3,21,64]. McNab and McKelvie
reported a diabetic patient with myelodysplasia
receiving monthly blood transfusions and 25 mg
of prednisolone per day who developed rhino-
orbito-cerebral mucormycosis; autopsy revealed
haemochromatosis [64]. Maertens et al. reported
that severe iron overload in bone marrow trans-
plant recipients was a risk factor for mucormyco-
sis. In their retrospective review of 263 allogeneic
bone marrow transplants, ﬁve cases of mucormy-
cosis were identiﬁed. All demonstrated iron
overload compared to a control group—mean
ferritin 2029 lg ⁄L vs. 608 lg ⁄L (p ¼ 0.0185), trans-
ferrin saturation 92% vs. 63% (p ¼ 0.0001), and
number of transfused units of blood 52 vs. 26 units
(p ¼ 0.0001), respectively [21]. Most infections
occurred in the late post-transplant period,median
343 days post-transplant (range, 90–534 days) [21].
Other studies, however, reported earlier develop-
ment ofmucormycosis,median 102–126 dayspost-
transplant (range, 12–470 days) [20,22].
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Deferoxamine, which acts as a siderophore,
was originally isolated from Streptomyces pilosus
[65]. Iron is a necessary growth factor for many
micro-organisms. In animal models of mucor-
mycosis, iron and deferoxamine promote the
growth and increase the virulence of Rhizopus
oryzae and Rhizopus microsporus [62,65].
Diabetics, especially those with ketoacido-
sis, are predisposed to rhino-orbito-cerebral
mucormycosis. In vitro, serum acidosis permits
the growth of Rhizopus spp. Normal serum inhib-
its the growth of Mucorales [62]. The capacity of
serum to bind iron falls signiﬁcantly when the pH
drops below 7.4 [66]. Artis et al. and Boelaert et al.
have shown that acidosis inhibits transferrin’s
capacity to bind iron, thus allowing Rhizopus spp.
to utilize it for growth in vitro. Artis et al. found
that the serum of four of seven diabetic ketoac-
idosis patients (pH 6.74–7.27) incubated with
R. oryzae spores supported profuse growth, but
inhibited growth when the pH was titrated to 7.4.
The three serum samples that did not support
growth, compared to those that did, had signiﬁ-
cantly lower iron levels, 13 lg ⁄dL vs. 69 lg ⁄dL,
respectively. The serum glucose level did not
affect growth irrespective of pH [66]. Impaired
neutrophil and macrophage function in diabetics
may also contribute to a risk of mucormycosis
[47,67–69].
Human immunodeﬁciency virus (HIV) infec-
tion does not appear to increase the risk of
developing mucormycosis probably because neu-
trophils, as opposed to T lymphocytes, play a
major role in defence against Mucorales
[3,11,70,71]. When mucormycosis does occur in
an HIV patient, it usually occurs in the context of
intravenous drug use. In a review of HIV patients
with mucormycosis, Van den Saffele and Boelaert
reported that 73% were intravenous drug users.
The majority developed cerebral, cutaneous, arti-
cular, or renal infection [70]. The majority of
intravenous drug users (80–85%) who develop
isolated cerebral mucormycosis are HIV negative
[70,72].
Other infections (e.g. malaria) may predispose
patients to Mucorales infection. Wilson et al.
reported a patient with severe Plasmodium falci-
parum malaria who developed disseminated Absi-
dia corymbifera and Aspergillus ﬂavus infection.
Possible predisposing factors include severe hae-
molysis, metabolic acidosis and immune suppres-
sion from malaria itself [73–75].
Cirrhosis, congenital heart disease, malnutri-
tion, carcinoma, anaemia, hepatitis, glomerulo-
nephritis, uraemia, amoebiasis, typhoid fever
and gastroenteritis have been associated with
mucormycosis [76].
Clinical manifestations
All species of Mucorales produce similar clinical
pictures [3]. The underlying medical condition
and associated risk factors determine which form
of mucormycosis develops.
Rhino-orbital-cerebral
Mucorales infects the head andneck region inwell-
deﬁned stages. Infection begins in the palate or the
paranasal sinuses, progresses to the orbit, and, if
not diagnosed early, to the brain. For simplicity the
term ‘rhino-orbito-cerebral mucormycosis’ will be
used to refer to any stage of this type of infection.
Rhino-orbito-cerebral mucormycosis is the most
common form of infection [10]. Rhizopus spp.
account for 70% of culture-positive cases reported
in the literature [77].
Signs and symptoms can include fever, leth-
argy, headache, orbital pain, abrupt loss of vision,
ophthalmoplegia, proptosis, ptosis, dilated pupil,
corneal anaesthesia and clouding, chemosis, peri-
orbital cellulitis, sinusitis, epistaxis, facial palsy,
trigeminal nerve distribution sensory loss and
seizures [10,77–79]. Cavernous sinus and internal
carotid artery thrombosis are also reported com-
plications [10,41,76–78]. Cerebrospinal ﬂuid ﬁnd-
ings are usually normal or nonspeciﬁc [41,76].
Rhino-orbito-cerebral mucormycosis has been
described classically in patients with diabetic
ketoacidosis or poorly controlled diabetes mellitus
[50,76]. It develops in leukaemia patients, usually
as a result of concomitant diabetes mellitus, or
high-dose corticosteroids [19,50,76]. Rhino-orbito-
cerebral mucormycosis has developed in many
other situations, such as following solid organ
and bone marrow transplant, b-thalassaemia,
trauma, burns, deferoxamine therapy, and even
polypous rhinosinusitis [49,50,80]. Rhino-orbito-
cerebral mucormycosis has been rarely reported
in HIV patients [71]. When rhino-orbito-cerebral
mucormycosis develops after trauma in an immu-
nocompetent host, one should consider Apophy-
somyces elegans as the possible pathogen [49]. Early
on, paranasal sinus involvement may manifest
as benign mucosal thickening on computed
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tomography. Bone destruction occurs later [80].
Mucorales invades the retro-orbital region and
frontal lobes by extending through the ethmoid or
sphenoid sinuses [76,81,82]. It can also invade the
brain through the superior orbital ﬁssure, ophthal-
mic vessels, perineural route, cribiform plate or the
carotid artery [10,41].
Black necrotic eschar visualized on the palate or
nasal mucosa has been the classically described
clinical clue of infection, however this lesion is not
invariably there on presentation. Ferry and Abedi
noted a black eschar on the skin, nasal mucosa or
palate in 19% (three of 16) of patients at presen-
tation, but the majority (68%) eventually devel-
oped this sign [78]. Yohai et al. noted nasal or
palatal ulceration, or necrosis in only 52% of
patients within 72 h of onset of signs and symp-
toms [77]. The absence of this ﬁnding should not
preclude considering the diagnosis.
Patients can develop a slowly progressive form
of rhino-orbito-cerebral mucormycosis with signs
and symptoms of more than 4 weeks duration
[41,79,81]. Harrill et al. reviewed 18 cases of
chronic mucormycosis, and found a median
duration of symptoms of 7 months. Sixty-seven
per cent of the patients had diabetes mellitus, and
83% had evidence of internal carotid artery or
cavernous sinus thrombosis. Despite this, the
overall survival rate was 83% [81].
Intravenous drug use places patients at risk for
isolated cerebral mucormycosis. The basal ganglia
were involved in 92% of cases reviewed by
Hopkins et al. [72]. Computed tomography of
the head reveals a variety of enhancement
patterns, from ring, to homogeneous, to none
[72]. The lesions may show minimal enhancement
on magnetic resonance imaging with gadolinium
contrast [72]. Such patients have been treated
successfully with a combination of surgery and
amphotericin B, and even amphotericin B alone
[72,83,84].
Indicators of poor prognosis include delay in
treatment (> 6 days), symptomatic intracranial
involvement with hemiplegia or hemiparesis,
bilateral sinus involvement, palatal involvement,
underlying leukaemia, deferoxamine therapy,
facial necrosis, or orbital involvement [41,77,85].
Effective therapy includes early diagnosis,
correction of any underlying reversible med-
ical condition, antifungal therapy, and surgical
debridement. In rhino-orbito-cerebral mucormy-
cosis, mortality rates vary from 30% to 69%
[41,50,77,78,85]. Anecdotally, nebulized ampho-
tericin B has been used as an adjunct to surgery
and intravenous liposomal amphotericin B in
sinonasal mucormycosis [80,86].
Pulmonary
This is the second most common site of involve-
ment of Mucorales infection [10,76]. Inhalation of
spores is the primary route of infection [9,87]. Its
clinical presentation is indistinguishable from that
of invasive pulmonary aspergillosis [87]. Males
appear to be over-represented in the medical
literature, with a male to female ratio of 2.3–3 : 1
[11,15].
Patients with leukaemia have traditionally been
considered to represent the majority of cases;
however, recent papers have suggested diabetes
mellitus to be the most prevalent underlying con-
dition [16,76]. Chakrabati et al. found that among
13 pulmonary cases, diabetes was the predispos-
ing factor in 23.1%, renal transplantation in
15.4%, malignancy in 7.7%, and corticosteroid
administration in 7.7% [16]. Tedder et al. re-
viewed 255 cases of mucormycosis that involved
at least the lungs; 39% had underlying haema-
tological malignancy, 32% had diabetes mellitus,
8% had undergone organ transplantation, and
18% had renal failure [15]. In a recent review of 87
cases of isolated pulmonary mucormycosis, Lee
et al. found that diabetics compromised the
majority [49 (56%)] of cases, followed by 28
patients (32%) with haematological malignancy,
11 (13%) with renal insufﬁciency, 10 (11%) with
prior organ transplantation, and 11 (13%) had no
apparent underlying disease [11]. These ﬁgures
do not, however, reﬂect the incidence of disease.
Patients with leukaemia, lymphoma and severe
neutropenia remain at greater risk of developing
pulmonary mucormycosis compared to other
forms of mucormycosis [19,47,76]. The apparent
equal or greater prevalence of diabetics with
pulmonary mucormycosis may be related
more to the greater number of patients with
diabetes compared to haematological malignan-
cies [47,76,88]. Patients with lymphoma may need
the added risk factor of diabetes to place them at
risk for infection. In a review by Meyer et al.
all mucormycosis patients with lymphoma had
diabetes, while only 29% of those with acute
leukaemia had concomitant diabetes [19]. Patients
with solid tumours rarely develop pulmonary
mucormycosis [2,12,49].
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Patients can present with cough, fever, haem-
optysis and ⁄ or pleuritic chest pain [5,11,87].
Leukocytosis need not be present [11,89]. Haema-
tology patients can have coexisting infection with
Aspergillus species, Candida species, bacteria, or
cytomegalovirus [5,11,19,21]. Lee et al. found
coinfection, mostly bacterial, in 32% of cases.
This could explain the initial response to antibac-
terial therapy occasionally noted [11].
Diabetics have an apparent predilection for
developing endobronchial lesions [87,90–92].
These patients represent 82–85% of endobronchi-
al cases in the literature [11,93]. Signs of endo-
bronchial involvement include a hoarse voice,
haemoptysis, mediastinal widening on chest
radiograph, lobar collapse and postobstructive
pneumonia [87,92]. These lesions can invade
major pulmonary blood vessels; patients usually
die from massive haemoptysis [92]. Surgical
resection is a necessity.
Pulmonary mucormycosis has a similar radio-
graphic appearance to aspergillosis. Both infec-
tions have a propensity to invade blood vessels
and produce thrombosis. Radiographic presenta-
tions include inﬁltrate, wedge-shaped consolid-
ation, nodule, cavitation, mycetoma, lobar collapse
and, rarely, pleural effusion [5,10,11,88,94]. The air
crescent sign, which typically suggests invasive
pulmonary aspergillosis, was present in 12% of 32
cases of mucormycosis reviewed by McAdams
et al. [90,95]. In the same review of mucormycosis
cases, 66% had consolidation and 41% had
cavitation on chest radiograph [90]. Crescentic
cavitation can develop either during the neutrop-
enic or postneutropenic phase [5,11,95].
Pulmonary mucormycosis in immunocompe-
tent hosts is not common [96,97]. When infec-
tion in an apparently immunocompetent host
does occur, symptoms can be present for several
months before diagnosis. For example, Zeilender
et al. reported an immunocompetent patient
with Cunninghamella bertholletiae pulmonary
infection who presented with a 4-month history
of productive cough, fever, chills and night
sweats [98].
Subacute (> 4–6 weeks of symptoms) pulmon-
ary, and even disseminated mucormycosis, cases
in diabetic patients have been reported [47,89]. Lee
et al. found that 18% of pulmonary mucormycosis
cases had symptoms for > 30 days [11].
Mortality rates of 60–100% have been reported
in haematology patients with focal pulmonary
infection [4,5,11,22,88]. Subacute pulmonary
mucormycosis may be more responsive to med-
ical therapy alone [4,47,95,99]. A combined surgi-
cal and medical approach is the most common
method of treatment.
Mucorales can produce an asymptomatic
mycetoma, similar to Aspergillus [8,76,87]. Hyper-
sensitivity pneumonitis to Rhizopus has been
reported in Scandinavian sawmill workers
(so-called woodtrimmer’s disease) and in farm
workers [100].
Cutaneous
Cutaneous mucormycosis can develop after a
break in the skin’s integrity from surgery, burns,
soiled trauma, motor vehicle accidents, bone
fractures, intravenous lines, insect bites, cactus
spine injuries, abrasions, lacerations, biopsy sites,
allergen patch testing, contaminated adhesive
tapes and intramuscular injections [13,17,56,101–
109].
Predisposing factors include diabetes, leukae-
mia and organ transplantation [24,42,56,110].
Cutaneous mucormycosis is the form of infection
least likely to be associated with underlying
disease [17,103]. In a review by Adam et al.
diabetes was present in only 26% of cutaneous
cases, compared to 67% of rhinocerebral, 21% of
disseminated, and 20% of pulmonary cases.
Leukaemia and ⁄ or neutropenia were found in
16% of cutaneous, 16% of rhinocerebral, 42% of
disseminated, and 48% of pulmonary cases
[102].
Cutaneous mucormycosis can manifest as a
superﬁcial or deep infection [102]. It can appear
as pustules, blisters, nodules, necrotic ulcera-
tions, echthyma gangrenosum-like lesions or
necrotizing cellulitis [107,111,112]. Skin biopsy
is required for diagnosis. Cultures and fungal
stains of wound swabs are not sensitive, and
may give misleading microbiological results
[111,113].
Of particular note, infections with A. elegans
and Saksenaea vasiformis occur predominantly in
tropical and subtropical climates (Australia, India,
Mexico, Venezuela, Aruba, South Carolina, Mis-
sissippi, Florida, Arizona, Texas, Caribbean)
[9,49,102,104,105,108,109,114,115]. They are both
thermophilic fungi that grow at warm incubation
temperatures (i.e. 43 C) [46]. Infection typically
develops in the extremities after trauma or in the
context of prior skin lesions [105].
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Historically, contaminated dressings have
caused hospital outbreaks of cutaneous
mucormycosis. Keys et al. reported a hospital
outbreak of R. oryzae skin infection from contam-
inated nonsterilized Elastoplast tape. Samples of
unused Elastoplast tape from the hospital and
the manufacturing plant both grew R. oryzae
[113,116]. Gartenberg et al. reported a similar
series of Rhizopus rhizopodiformis-contaminated
Elastoplast tape related infections [113]. Cutane-
ous mucormycosis from contaminated dressings
has not been reported recently [102].
Cutaneous mucormycosis portends a better
prognosis than other forms of mucormycosis. In
a review of 11 cases of cutaneous mucormycosis
from one institution over a 25-year period, Adam
et al. found that all patients survived. In a review
of the medical literature, cutaneous involvement
had the lowest mortality (16%), compared to 67%
for rhinocerebral, 83% for pulmonary, and 100%
for disseminated and gastrointestinal mucor-
mycosis [102]. Complete resection of necrotic
and infected tissue is the key to successful
therapy. Cutaneous mucormycosis presentation
varies from indolent to a rapidly progressive
infection requiring surgical debridement, antifun-
gal therapy, or even amputation [102].
Disseminated
Disseminatedmucormycosis involves two ormore
noncontiguous organs. Neutropenic patients with
leukaemia or lymphoma comprise the majority of
patients with disseminated mucormycosis [4,89].
Dissemination occurs in 23–62% of cases with
haematologicalmalignancy [3,4,6,19,22,117]. Other
risk factors for dissemination include organ trans-
plantation, chemotherapy, corticosteroids and def-
eroxamine therapy [4,6,16,61]. Many patients are
coinfected with other bacterial, viral or fungal
pathogens [6,76]. The mortality rate for dissemin-
ated disease approaches 100% [3,15,117].
Gastrointestinal
The signs and symptoms of gastrointestinal
mucormycosis are nonspeciﬁc, and include
abdominal pain, haematemesis and melena
[40,118,119]. Patients who have undergone organ,
bone marrow or peripheral blood stem cell
transplantation, and those with acute myelogen-
ous leukaemia, lymphoma, diabetic ketoacidosis,
nonketotic diabetes mellitus, amoebic colitis,
typhoid fever, pellagra, kwashiorkor, malaria,
malnutrition, meningococcaemia and prematurity
have developed gastrointestinal mucormycosis
[10,43,118,120–124].
Gastrointestinal mucormycosis has rarely
occurred after renal, liver and heart transplanta-
tion [118,125–127]. Oliver et al. reported a bone
marrow transplant patient with graft-versus-host
disease who developed Mucor indicus hepatic
mucormycosis after consuming naturopathic
medicine. M. indicus was recovered from the
hepatic abscess and naturopathic medicine. Both
were identical by arbitrary-primed polymerase
chain reaction analysis [128].
One third of the cases of gastrointestinal mu-
cormycosis occur in infants and children [10,43].
In children less than 1 year of age, the stomach
(59%) and colon (53%) have been the most
commonly involved sites, followed by the small
bowel (24%) [43]. In children aged 2–18 years the
stomach has been involved in 85% of cases,
oesophagus in 38% of cases, small bowel in 31%
of cases, and colon in 31% of cases [43]. Mal-
nutrition has been present in 50% of cases [43].
Overall, the most frequent segments involved are
the stomach, followed by the large bowel [10,76].
Intestinal mucormycosis is rare in the normal
host. Calle and Klatsky described a case in
an apparently immunocompetent 23-year-old
African-American woman [119]. The autopsy,
however, demonstrated haemosiderosis of the
liver and spleen, raising the possibility of iron
overload. Gastric mucormycosis has developed
after nasogastric intubation and in the presence of
known gastric ulcers [21,43,116,123,129].
Surgical intervention is usually necessary given
the high risk of gastrointestinal perforation and
exsanguination [122].
Miscellaneous
Mucormycosis is a rare cause of prosthetic valve
endocarditis [63,130,131]. Native valve endocar-
ditis with C. bertholletiae and S. vasiformis has been
reported [12,132].
Kalayjian et al. reported an unusual case of
Mucorales causing aortic thrombosis in a patient
with myelodysplastic syndrome. At autopsy,
hyphal invasion throughout the entire thickness
of the aortic wall, with no organ involvement, was
noted [54].
Isolated renal mucormycosis has developed in
intravenous drug users. It has also occurred in
patients who have undergone renal transplanta-
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tion in warmer climates and developing countries
such as India, Egypt, Saudi Arabia, Kuwait and
Singapore [26,57,133].
Osteomyelitis usually occurs after traumatic
inoculation or surgical intervention (i.e. tibial pin
placement, anterior cruciate ligament repair)
[134–136]. Osteomyelitis of the tibia, cuboid,
calcaneus, femur, humerus, scapula, metacarpals,
phalanges and sternum have been reported
[94,114,135–138]. Haematogenous osteomyelitis
is extremely rare [138].
Diagnosis
A diagnosis of mucormycosis is rarely suspected
among haematology patients as most physicians
presume a diagnosis of invasive aspergillosis. In
haematology patients an ante mortem diagnosis
of mucormycosis is made in only 23–50% of cases
[4–6,21,117]. Computed tomography of the chest
might identify inﬁltrates suggestive of mucor-
mycosis not documented by standard chest radio-
graph [4,90]. The poor sensitivity of sputum
culture (25%) makes diagnosis challenging [6].
The yield of bronhoalveolar lavage is not higher
[6,88,90]. Direct microscopy of bronchoalveolar
lavage together with transbronchial biopsy may
increase the yield [87,88]. It may be difﬁcult to
obtain a transbronchial biopsy given that many
haematology patients are thrombocytopenic. A
positive ﬁnding from bronchoalveolar lavage
from a neutropenic or immunocompromised host
would be highly suggestive of infection, and
should be treated as such [87,88,99]. Histological
examination of biopsied tissue is the preferred
method of diagnosis. Invasion seen on histo-
pathology is needed to conﬁrm a diagnosis [10].
Polymerase chain reaction may become a diag-
nostic modality to identify these organisms [139].
Rickerts et al. diagnosed disseminated C. bertholle-
tiae infection in a leukaemic patient using a
polymerase chain reaction assay targeting 18S
ribosomal DNA in blood. The diagnosis was
conﬁrmed by positive cultures from bronchoalvel-
olar lavage and pleural ﬂuid. Such an approach
also holds promise for the diagnosis of invasive
aspergillosis [139,140].
Treatment
Treating a patient’s underlying medical condi-
tion and reducing immunosuppression are essen-
tial to therapy [87]. Diabetics may have a more
favourable outcome than nondiabetics. Yohai
et al. reported an overall survival rate for rhino-
orbito-cerebral mucormycosis of 77% in diabetics
and 34% in nondiabetics [77]. Blitzer et al. made a
similar observation in rhino-orbito-cerebral
mucormycosis patients with a 60% survival rate
among diabetics and 20% in nondiabetics [85].
Those with severe underlying diseases, such as
leukaemia and lymphoma, tend to have poorer
outcomes [76]. The mortality rate for isolated
pulmonary mucormycosis varies from 9.4 to 27%
with a combined surgical and medical approach,
compared to 50–55% for those treated only
medically [11,15]. Notably, there is inherent selec-
tion bias in reported cases, and in candidates for
types of therapy [11].
The mainstay of treatment is antifungal therapy
with an amphotericin B preparation (Table 3),
surgery, and correction of the underlying medical
condition if possible. Amphotericin B is the only
available antifungal agent with signiﬁcant in-vitro
activity against Zygomycetes. Caspofungin and
5-ﬂucytosine are resistant in vitro to Mucorales
[150,193]. Amphotericin B and its lipid formula-
tions have been successfully used to treat mu-
cormycosis [1,99,141,192].
Certain Mucorales species have variable sus-
ceptibilities to amphotericin B. Garey et al. found
that the mean inhibitory concentrations (MIC) of
Cunninghamella clinical isolates ranged from
<1 lg ⁄mL to 100 lg ⁄mL. They reported a case
of C. bertholletiae infection in an allogeneic bone
marrow transplant recipient unsuccessfully trea-
ted with two different lipid formulations of
amphotericin B (amphotericin B liposomal and
lipid complex). The MIC according to National
Committee for Clinical Laboratory Standards
Table 3. Most frequently used antifungal agents to treat
mucormycosis and entomophthoramycosis
Mucormycosis
Amphotericin B deoxycholate (Fungizone) [5,22]
Amphotericin B cholesterol sulfate complex
(Amphotec, Amphocil) [1]
Liposomal amphotericin B (AmBisome) [49,59,99,109]
Amphotericin B lipid complex (Abelcet) [83,190]
Entomophthoramycosis
Potassium iodide [167,174,175]
Itraconazole [169,171,176,179]
Ketoconazole [175]
Miconazole [181,183]
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(NCCLS) guidelines was 4 lg ⁄mL. Amphotericin
B lung concentrations from surgically removed
tissue were on average 9.5 lg ⁄mL after having
received more than 10 g of liposomal amphoter-
icin. Amphotericin B may not achieve satisfactory
levels at the site of involvement because of tissue
infarction and thrombosis [142].
Anecdotal case reports exist concerning the
treatment of mucormycosis with ﬂuconazole and
itraconazole [143–145]. Funada et al. reported a
29-year-old woman with acute myelogenous
leukaemia with pulmonary mucormycosis who
appeared to respond clinically and radiographi-
cally to ﬂuconazole. The response, however, may
have been secondary to a recovering neutrophil
count [146]. Most in-vitro and animal studies have
shown poor efﬁcacy of azoles [51,145,147–150].
Azoles were not effective against Rhizopus
infection in guinea-pig and murine models [145].
Itraconazole was inferior to amphotericin B in
murine models of disseminated Absidia and
Rhizopus infection [145,147]. There is some
experimental murine data to suggest activity
of ﬂuconazole in combination with ciproﬂoxa-
cin or trovaﬂoxacin in pulmonary mucormycosis
[151]. Voriconazole, in vitro, shows no useful
activity against Mucorales [148,150]. Posacona-
zole, a new triazole under development, shows
promise as an effective alternative agent against
Mucorales [191].
Correction of the underlying medical condi-
tion is essential for successful therapy, as dem-
onstrated by a rare case of documented cavitary
pulmonary mucormycosis by Rhizopus sp. that
resolved without antifungal therapy after correc-
tion of diabetic ketoacidosis [152]. Abraham et al.
reported a case of asymptomatic pulmonary
mucormycosis in a man with Graves’ thyrotoxi-
cosis that resolved without antifungal therapy
[148–150].
Recovery of neutrophils plays a signiﬁcant role
in successful resolution of this infection in neu-
tropenic patients [95,141]. Funada et al. reported a
patient with acute myelogenous leukaemia with
documented pulmonary mucormycosis who was
successfully treated with amphotericin B and
5-ﬂucytosine alone. Recovery from neutropenia
was considered of vital importance for this
patient’s recovery [95]. Roy et al. successfully
treated disseminated (brain, lung, skin) Mucor
and Aspergillus species infection in a patient who
had relapsed 10 months after allogeneic bone
marrow transplantion for non-Hodgkin’s lym-
phoma by using amphotericin B lipid complex
(5 mg ⁄ kg daily) and itraconazole (200 mg twice
daily) alone. Re-induction of remission through
donor lymphocyte infusion and neutropenia reso-
lutionappeared toplay critical roles for his survival
[141].
Granulocyte–macrophage colony-stimulating
factor (GM-CSF) and granulocyte colony-stimula-
ting factor (G-CSF) have been used adjunctively to
treat mucormycosis in neutropenic and non-neu-
tropenic patients [49,99,153–156]. Anecdotally,
granulocyte transfusions have been used as an
additional treatment measure in neutropenic
patients [141, 194].
There are multiple reports on the use of
adjunctive hyperbaric oxygen [49,50,157–163]. A
typical regimen uses 100% oxygen at two atmos-
pheres for 90 min twice a day [50]. In vitro, there
is no effect of pressure alone on the growth of
fungi [164]. In vitro, R. oryzae is inhibited by a 2-h
exposure to 100% oxygen at one atmosphere
[50,165]. In a deferoxamine-treated mouse model
of mucormycosis, Barratt et al. found no beneﬁt of
adjunctivehyperbaric oxygencompared toampho-
tericin B alone [166].
In a retrospective review, Ferguson et al.
observed that hyperbaric oxygen, amphotericin
therapy, and surgical debridement were associ-
ated with a statistically insigniﬁcant lower mor-
tality than were amphotericin B therapy and
surgical debridement alone. In a retrospective
review of mucormycosis, Yohai et al. found a
higher survival rate with standard therapy and
hyperbaric oxygen compared to standard therapy
alone, 83% (ﬁve of six patients) vs. 22% (four of 18
patients) (p ¼ 0.0285) [77]. Such studies are limited
by their small sample size and the lack of random-
isation [50]. A randomised trial is unlikely to be
performed, given the rarity of this infection, and
patients’ variable comorbidities and severity of
illness [50].
ENTOMOPHTHORAMYCOSIS
Infection with fungi from the order Entomophtho-
rales, Conidiobolus coronatus, Conidiobolus incongru-
us and Basidiobolus ranarum, typically occurs in
immunocompetent patients residing in subtropical
and tropical climates [167]. Unlike Mucorales,
Entomophthorales do not cause angioinvasive
disease [9,168–171].
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Basidiobolomycosis
Basidiobolomycosis is a chronic infection of the
subcutaneous tissue caused by B. ranarum. This
organism resides in decaying plant material, soil,
leaves from deciduous trees, and the intestines of
ﬁsh, frogs, toads, insects, reptiles and insectivor-
ous bats [167,172,173]. Many case reports and
series of subcutaneous basidiobolomycosis come
from Africa (especially Uganda and Nigeria),
India, and South-east Asia [167,169]. B. ranarum
usually infects children [172,174,175]. Mugerwa
reviewed 80 cases from Uganda and found that
76% of patients were under 10 years of age, and
88% under 20 years of age [172].
Basidiobolomycosis mainly involves the thigh,
buttock or trunk [172,174,175]. Mugerwa sugges-
ted that the use of ‘toilet leaves’ to clean after
defecation might explain the observed distribu-
tion of lesions and source of infection [172].
Painless erythematous ﬁrm indurated plaques of
the subcutaneous tissue are characteristic [167].
Signiﬁcant nonpitting oedema of the involved
extremity may occur. Skin ulceration and lymph
node enlargement have been reported [174,175].
B. ranarum are pauciseptate on histopathology,
but more septate than are Mucorales.
B. ranarum rarely involves the gastrointesti-
nal tract, as has been described in Arizona,
Florida, Utah, Nigeria, Brazil and Kuwait
[169–171,176–179]. Patients can present with
abdominal pain, constipation, diarrhoea, nausea,
vomiting, bloody mucous discharge, fever and
weight loss [167,169–171,177]. Gastrointestinal
basidiobolomycosis is associated with mural
thickening, nodular masses, and ulcerations of
the intestine that resemble Crohn’s disease. It can
involve the stomach, small intestine, colon or
rectum [179]. Invasive sinusitis has also been
reported rarely [180].
Conidiobolomycosis
Conidiobolus spp. typically cause a chronic, indolent
infection of the face [173,175,181]. Cases have been
reported from West Africa, South America, India,
Saudi Arabia, Oman and Taiwan [173,175,181–
185].Conidiobolus spp. cause a progressive swelling
mass over the nasal submucosa, nose, eyelids, and
over the malar and frontal regions of the face.
Conidiobolomycosis has been rarely reported to
involve the nasolacrimal duct and orbit [182,183].
The most common symptoms include nasal
obstruction, nasal discharge or chronic sinusitis.
Surgery alone is usually not curative [183].
Invasive infection is rare. Jaffey et al. described
a case of a cocaine abuser who developed dis-
seminated Conidiobolus sp. infection with endo-
carditis and fungal vasculitis. The species was not
consistent with C. congruus or C. coronatus [186].
Walsh et al. reported a case of pulmonary and
cardiac involvement with angioinvasion in a
patient with lymphoma [187].
Diagnosis
Histopathologic examination usually shows
dense eosinophilic granular inﬁltrates surround-
ing hyphal elements, the so-called Splendore–
Hoeppli phenomenon. The inﬂammatory inﬁl-
trate is mixed with eosinophils, histiocytes,
neutrophils, lymphocytes, plasma cells and giant
cells [167–169,172,174,175]. This reaction is not
seen in mucormycosis. Patients may have leuko-
cytosis and peripheral eosinophilia [174].
Serology testing is not widely available. Khan
et al. detected B. ranarum antibodies with immuno-
diffusion and ELISA tests [178]. Kaufman et al.
also devised an immunodiffusion test to detect
both Conidiobolus and Basidiobolus. The assay was
100% sensitive and speciﬁc [188].
Treatment
Potassium iodide, miconazole, cotrimoxazole,
ketoconazole, itraconazole, amphotericin B, terbin-
aﬁne, hyperbaric oxygen and surgical debridement
have been used in various combinations with
variable success (Table 3) [167,173–176,181,
183–185]. Guarro et al. performed susceptibility
testing on nine Basidiobolus spp. and eight Conid-
iobolus spp. isolates. The geometric mean MIC
values for Basidiobolus spp. were lower than for
Conidiobolus spp.: itraconazole, 1.8 vs. 11.3 lg ⁄mL;
ketconazole, 1.0 vs. 20.7 lg ⁄mL;miconazole, 3.9 vs.
11.3 lg ⁄mL; amphotericin B, 2.7 vs. 3.1 lg ⁄mL;
ﬂuconazole, 14.8 vs. 107.5 lg ⁄mL; and ﬂucytosine,
165.9 vs. 234.6 lg ⁄mL [189]. There is no clinical
experience in treating entomophthoramycosis
with voriconazole. Krishnan et al. had good
success with potassium iodide at 40 mg ⁄kg ⁄day
in 9 of 10 patients seen with either conidiobolomy-
cosis or basidiobolomycosis over a 4-year period
[175]. Clinical failure has been reported with
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amphotericin B [171,181]. Itraconazole or potas-
sium iodide seem reasonable ﬁrst-line choices
[171,179]. No single agent has reliable consistent
antifungal activity [181]. In-vitro susceptibility
testing may be helpful in guiding therapy [181].
CONCLUSIONS
Infections with fungi from the orders Muco-
rales and Entomophthorales are uncommon.
Mucormycosis typically affects the immunocom-
promised host; however healthy patients with
some form of trauma and the right history of
environmental exposure can develop infection as
well. In the future, more cases of mucormycosis
may be encountered because of increasing num-
bers of immunocompromised patients (i.e. solid
organ, bone marrow and peripheral blood stem
cell transplant recipients). The mainstay of suc-
cessful therapy remains early diagnosis with
aggressive surgical debridement, in conjunction
with an intravenous amphotericin B product.
Adjunctive measures such as hyperbaric oxygen
and GM-CSF have theoretical advantages in
treating mucormycosis. Unfortunately, random-
ised clinical trials to clarify the role of these
measures are unlikely to take place given the
rarity of this infection. The development and
utility of molecular assays to aid in early diagno-
sis need further exploration.
Entomopthoramycosis is clinically distinct
from mucormycosis. However, seen predomin-
antly in subtropical and tropical climates, physi-
cians should be aware of this infection given the
increase in global travel.
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